Piper Jaffray Starts Alder Biopharm (ALDR) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Alder BioPharma (ALDR) Tops Q3 EPS by 15c
October 27, 2016 4:16 PM EDTAlder BioPharma (NASDAQ: ALDR) reported Q3 EPS of ($0.70), $0.15 better than the analyst estimate of ($0.85).
For earnings history and earnings-related data on Alder BioPharma (ALDR) click here.
... More